EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Elexacaftor/tezacaftor/ivacaftor’s effects on cystic fibrosis infections are maintained, but not increased, after 3.5 years of treatment

Sarah J Morgan, Ellis Coulter, Hannah L Betts, George M Solomon, John P Clancy, Steven M Rowe, David P Nichols, Pradeep K Singh, PROMISE-Micro Study Group

Journal of Clinical Investigation · 15.10.2024 · 134 (20)

DOI: 10.1172/jci184171 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 05.09.2024. Verfasst von Sarah J Morgan und 8 weiteren Autor:innen. Beteiligte Einrichtung: University of Washington, Seattle, Washington, USA. Hauptthemen laut MEDLINE: Cystic Fibrosis, Benzodioxoles, Aminophenols, Indoles. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 3 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, NHLBI NIH HHS, Cystic Fibrosis Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisBenzodioxolesAminophenolsIndolesQuinolonesPyrazolesDrug CombinationsHumansMaleFemalePyridinesPyrrolesAdolescentChildAdultPseudomonas InfectionsPyrrolidinesQuinolinesCystic Fibrosis Transmembrane Conductance Regulator

Stichwörter der Autor:innen

Bacterial infectionsMicrobiology

Substanzen

BenzodioxolesAminophenolsIndolesQuinolonesPyrazolesDrug CombinationsivacaftorelexacaftorPyridinesPyrroles

Autor:innen und Institutionen

  • University of Washington, Seattle, Washington, USA.
  • University of Alabama, Birmingham, Alabama, USA.
  • Cystic Fibrosis Foundation, Bethesda, Maryland, USA.

Förderung

  • NIDDK NIH HHS
  • NHLBI NIH HHS
  • Cystic Fibrosis Foundation
  • NHLBI Division of Intramural Research

Zitieren

APA

Morgan, S. J., Coulter, E., Betts, H. L., Solomon, G. M., Clancy, J. P., Rowe, S. M., Nichols, D. P., Singh, P. K., & PROMISE-Micro Study Group (2024). Elexacaftor/tezacaftor/ivacaftor’s effects on cystic fibrosis infections are maintained, but not increased, after 3.5 years of treatment. Journal of Clinical Investigation, 134(20). https://doi.org/10.1172/jci184171

Vancouver

Morgan SJ, Coulter E, Betts HL, Solomon GM, Clancy JP, Rowe SM, et al. Elexacaftor/tezacaftor/ivacaftor’s effects on cystic fibrosis infections are maintained, but not increased, after 3.5 years of treatment. Journal of Clinical Investigation. 2024;134(20). doi:10.1172/jci184171

BibTeX
@article{Morgan2024,
  author = {Morgan, Sarah J and Coulter, Ellis and Betts, Hannah L and Solomon, George M and Clancy, John P and Rowe, Steven M and Nichols, David P and Singh, Pradeep K and PROMISE-Micro Study Group, PROMISE-Micro Study Group},
  title = {Elexacaftor/tezacaftor/ivacaftor’s effects on cystic fibrosis infections are maintained, but not increased, after 3.5 years of treatment},
  journal = {Journal of Clinical Investigation},
  year = {2024},
  volume = {134},
  number = {20},
  doi = {10.1172/jci184171}
}
Kostenlos starten →